Phase 1 N=30 Evaluation of Safety of Repeated Doses of OP0201 Metered Dose Inhaler Compared to Placebo in Healthy Adult Volunteers
Healthy Adult Volunteers
Primary: Number of Participants With of Adverse Events — 5; 9; 4 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=59 Study to Show a Superior Benefit in Terms of Reduction of Ranibizumab Injections in Patients Receiving Ranibizumab Plus Laser Photocoagulation Combination Therapy Without Loss of Efficacy and Safety
Macular Edema Secondary to Branch Retinal Vein Occlusion (BRVO)
Primary: Difference in Mean Number of Ranibizumab Injections — 4.3; 4.1 number of injections — p=0.3680
N/A N=1,090 Cornea Donor Study
Corneal Disease · Fuch's Dystrophy · Pseudophakic Corneal Edema
Primary: Graft Failure — 142; 82 participants
N/A N=407 Non-interventional Study of Moderate to Severe Inflammatory Bowel Disease in Brazil
Inflammatory Bowel Disease
Primary: Percentage of Participants With Active Crohn's Disease (CD) at Day 1 — 16.52; 25.97 percentage of participants
N/A N=12 An Evaluation of Protective Effects of OpalSeal™ Against Early Dental Decay in Orthodontic Patients
Cavities of Teeth
Primary: Loss of Mineral Density in the Enamel — 70.8; 77.4 microns
Phase 4 N=136 Omalizumab in Chronic Spontaneous Urticaria Patients Non Responding to Initial Standard antihistaminE Treatment
CHRONIC SPONTANEOUS URTICARIA
Primary: Percent of Participants With an Urticaria Control Test [UCT] Score of Greater Than or Equal to 12 — 75.0 percent of participants
N/A N=20 Ventricular Assist Device Anti-Factor Xa (VAD ANTIX) Monitoring Study: a Prospective Randomized Feasibility Trial
Left Sided Heart Failure · Left Ventricular Assist Device · Anticoagulant Therapy
Primary: Nomogram Feasibility — 136; 112; 136; 111 Surveys — p=.45
N/A N=19 Supplemental Oxygen in Pulmonary Fibrosis
Pulmonary Fibrosis
Primary: Change in University of California San Diego Shortness of Breath Questionnaire From Immediately Prior to One Month After Starting Daily-use Supplemental Oxygen — 0.9…
Phase 3 N=123 Incidence of Hypophosphatemia After Treatment With Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia
Iron Deficiency Anaemia · Iron Deficiency Anemia
Primary: Incidence of Hypophosphatemia (S-phosphate Level <2 mg/dL) — 5; 45 Participants — p=<0.0001
Phase 3 N=157 2% Chlorhexidine Gluconate Skin Cloths to Prevent SSI in Spine Surgery Patients
Surgical Site Infections · Post Operative Complication
Primary: Participants With Surgical Site Infection Development at 30 Days Post-operative — 5; 5 Participants — p=0.456
Phase 2 N=282 Clofarabine, Idarubicin, and Cytarabine (CIA) Versus Fludarabine, Idarubicin, and Cytarabine (FLAI) in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome
Leukemia
Primary: Maximum Tolerated Dose (MTD) of Clofarabine, Idarubicin, and Cytarabine — 15 mg/m^2
Phase 2 N=19 Phase 2 Clinical Trial of SGS-742 Therapy in Succinic Semialdehyde Dehydrogenase Deficiency
Metabolic Disease · Seizures
Primary: Change From Baseline on the Adaptive Behavior Assessment System (ABAS) Test at the End of the Study Drug and Placebo Treatment Periods — 5.2; 4.5 scores on a scale
N/A N=256 Pain Outcomes Comparing Yoga Versus Structured Exercise (POYSE) Trial
Fibromyalgia
Primary: Fibromyalgia Impact Questionnaire Revised (FIQR) Total Score — 41.5; 42.2 units on a scale
N/A N=13 PET/MRI and PET/CT in Diagnosing Younger Patients With Cancer
Childhood Cancer
Primary: Diagnostic Accuracy of PET/MRI
Phase 2 N=75 Safety and Efficacy of CBT-001 Ophthalmic Solution in Patients With Pterygium
Pterygium
Primary: Pterygium Vascularity Change Assessed Using the Pterygium Hyperemia Grading Scale — 0; -0.8 grade — p=<0.001